(Press-News.org) SEATTLE – July 15, 2025 – Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests. Researchers will evaluate whether these blood tests will help people ages 45 to 75 find cancer early when it may be easier to treat.
This is the first study of the Cancer Screening Research Network (CSRN), a nationwide network that will run trials aimed at improving cancer screening that is funded by the National Cancer Institute (NCI), part of the National Institutes of Health. Fred Hutch serves as the Coordinating and Communications Center as well as the Statistics and Data Management Center.
Multi-cancer detection tests use blood samples to detect biological substances released in the bloodstream by cancer cells or in human DNA. Each MCD test screens for several kinds of cancer, and the MCD tests in the Vanguard study will screen for the following cancers: bladder, breast, colorectal, esophageal, stomach, liver, lung, ovarian, pancreatic and prostate.
“There is excitement around these new screening tools with their potential to diagnose cancer earlier, when we expect treatment to be more effective and tolerable,” said Ruth Etzioni, Ph.D., biostatistician at Fred Hutch and one of the principal investigators of the CSRN. “The Vanguard Study and Cancer Screening Research Network will be able to help us understand how these tools are best used.”
The Fred Hutch team has expertise leading large-scale clinical trial networks and complex studies similar to CSRN, including the Women’s Health Initiative, HIV Vaccine Trials Network, COVID-19 Prevention Trials Network as well as the Statistical and Data Management Center for SWOG, a national oncology group. In addition to their expertise leading large trials, researchers at Fred Hutch are at the forefront of cancer detection and prevention research having led the NCI-sponsored Early Detection Research Network for 25 years.
“Fred Hutch is a leader in team science,” said Garnet Anderson, Ph.D., Director of Public Health Sciences Division at Fred Hutch and one of the principal investigators of the CSRN. “We bring together top scientists and diverse perspectives to answer important public health questions, in this case – do multi-cancer detection tests work? And if so, what are the clinical pathways needed to make an impact on cancer?”
Current screening tests exist for breast, cervical, colorectal, prostate and lung cancers, yet most cancers don’t have any screening methods. According to the American Cancer Society, nearly half of all cancers diagnosed annually are cancers with no recommended screening tests. These cancers are often found at later stages when they can be harder to treat.
The Vanguard study will recruit adults ages 45 to 75 with no cancer diagnosis in the past five years. Participants will give two blood samples, one at entry and another one year later, and complete regular cancer screening as recommended by clinicians. At entry, they will be randomized into one of the three arms of the study: a control group, a group that receives the Avantect® MCD Test by ClearNote Health, or a group that receives the ShieldTM MCD Test by Guardant Health.
“We need to rigorously evaluate multi-cancer detection tests to understand if they’re effective and accurate cancer screening tools for everyone,” said Scott Ramsey, M.D., Ph.D., principal investigator of the CSRN and cancer researcher at Fred Hutch Cancer Center.
The Vanguard Study is a pivotal first step in evaluating the feasibility of conducting large-scale randomized clinical trials to assess the effectiveness of MCD tests and other emerging cancer screening technologies. Its findings will help shape the rigorous design and implementation of future studies aimed at advancing early cancer detection, including a large national trial to determine if MCD tests decrease cancer burden and mortality.
Individuals interested in the study can visit the Vanguard Study website to learn more about the study, what local sites near them are recruiting, and their eligibility to participate.
# # #
Media Contact:
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.
Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program.
END
Advances in blood stem cell transplants now make it possible for people with blood cancers to get safe and effective “mismatched” transplants that will potentially cure their disease, new UVA Cancer Center research reveals. The advances will allow far more people to receive the lifesaving treatment.
Patients who could not find a perfect match traditionally have not received transplants because of the potential for graft-versus-host disease. This occurs when the immune system recognizes the transplanted cells as foreign and attacks them. This can be serious and, ...
The Qinghai-Xizang Plateau (QP), often referred to as the "Asian Water Tower", is a vital source of water for nearly two billion people. Understanding how precipitation patterns in this region will change in the coming decades is crucial for water resource management and climate adaptation. However, projecting near-term precipitation changes has been challenging due to significant uncertainties in climate models.
A new study published in Atmospheric and Oceanic Science Letters addresses this issue by analyzing near-term (2026–2055) precipitation projections for the QP using 100 ensemble members from the MPI-ESM climate model. The research ...
OAK BROOK, Ill. – An AI model trained to detect abnormalities on breast MR images accurately depicted tumor locations and outperformed benchmark models when tested in three different groups, according to a study published today in Radiology, a journal of the Radiological Society of North America (RSNA).
“AI-assisted MRI could potentially detect cancers that humans wouldn’t find otherwise,” said the study’s lead investigator Felipe Oviedo, Ph.D., a senior research analyst at Microsoft’s AI for Good Lab.
Screening mammography is considered the standard of care in breast ...
WASHINGTON — In a new mouse study, researchers have used optical coherence tomography (OCT) to uncover new insights into how the fallopian tube transports preimplantation embryos toward the uterus for pregnancy. These findings help lay the foundation for understanding certain causes of infertility and pregnancy complications in people.
The fallopian tube, also known as the oviduct, is a tubular structure that connects the ovary and the uterus. It is responsible for several critical processes that lead to pregnancy, including transporting eggs and sperm, hosting fertilization and transporting preimplantation embryos as they develop.
“Most of the oviduct’s ...
The Hong Kong Polytechnic University (PolyU) is committed to driving cutting-edge research that creates societal impact and technological advancement. Prof. YANG Hongxia, Executive Director of the PolyU Academy for Artificial Intelligence, Associate Dean (Global Engagement) of the Faculty of Computer and Mathematical Sciences, and Professor of the Department of Computing, has received funding from the Theme-based Research Scheme 2025/26 under the Research Grants Council for her pioneering project, “Collaborative Generative AI (Co-GenAI)”.
The project has been awarded total funding of HK$62.6 million, with HK$41.79 million provided by the RGC and the remaining ...
GRAND RAPIDS, Mich. (July 15, 2025) — Van Andel Institute scientists have developed an improved technique to comprehensively profile DNA methylation in single cells, an advance that will help researchers better study the role of epigenetics in cancer and other diseases.
DNA methylation is an epigenetic mechanism that influences how and when the instructions in DNA are used without changing the DNA sequence itself. As a result, DNA methylation is a key player in many fundamental biological processes ...
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA (TLI) announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a new grant (P01AI186818) to Dr. Ashraf S. Ibrahim, PhD, a TLI Investigator, a Professor of Medicine at David Geffen School of Medicine at UCLA, and a leading authority on mucormycosis pathogenesis. The grant provides $2.2 million in first-year funding and $11,269,858 million in total projected support over ...
The United States could safely drop tetanus and diphtheria booster shots for adults and save an estimated $1 billion a year, according to a new review led by researchers at Oregon Health & Science University.
The safety and savings depend on maintaining strong childhood vaccination rates, researchers emphasized.
“By maintaining high childhood vaccination coverage, we not only protect kids, but we may actually be able to reduce adult booster vaccinations,” said lead author Mark Slifka, Ph.D., professor of microbiology and immunology in the OHSU School of Medicine and the Oregon National Primate Research Center. “That would save $1 billion a year in the U.S. while maintaining ...
On July 1, 2025, Rebecca Schaumberg joined ESMT Berlin as an assistant professor of organizational behavior.
Rebecca Schaumberg’s research combines psychological theory with business practice and focuses on the role of self-conscious emotions such as shame, guilt, pride, and embarrassment in organizational contexts. Her work shows how these emotions shape decision-making, leadership processes, and organizational cultures. Her research has been published in leading academic journals, including Psychological Science, Academy of Management Journal, and Organizational Behavior and Human Decision Processes.
Schaumberg ...
New York, NY, July 15, 2025—Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung-scarring disease. Their findings, demonstrated across cell cultures, preclinical models, and samples of human lung tissue, show that blocking Epac1 can slow the progression of the disease.
Published in the July 7 online issue of European Respiratory ...
